Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical response to morphine in cancer patients and genetic variation in candidate genes.

The pharmacogenomics journal - 1 Jan 2005

Ross J R, Rutter D, Welsh K, Joel S P, Goller K, Wells A U, Du Bois R, Riley J

Abstract excerpt

Morphine is the analgesic of choice for moderate to severe cancer pain; however, 10-30% of patients do not tolerate morphine. This study evaluated genetic variation in the mu-opioid receptor, betaarrestin2, stat6 and uridine diphosphate-glucuronysltransferase 2B7 (UGT2B7) genes, in patients who responded to morphine vs those who were switched to alternative opioids. We prospectively recruited and genotyped 162...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Analgesics, Opioid
Share to Arrestins
Share to beta-Arrestins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glucuronosyltransferase

Share to Morphine

Share to Nausea

Share to Pain Measurement

Share to Receptors, Opioid, mu

Source

Identifiers

PMID: 16103897
DOI: 10.1038/sj.tpj.6500327

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical response to morphine in cancer patients and genetic variation in candidate genes.PMID 16103897Read ↗

Clinical trials of cancer-related pain : translational research linking genetic variation to pain experience and response to oral opioidsSemantic proximity Read ↗

Clinical Implications of Opioid Pharmacogenomics in Patients With Cancer.Semantic proximity Read ↗

Genetics and Opioids: Towards More Appropriate Prescription in Cancer PainSemantic proximity Read ↗

Pain polymorphisms and opioids: An evidence based reviewSemantic proximity Read ↗

Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy.Semantic proximity Read ↗

Pharmacogenetics of Opioid ResponseSemantic proximity Read ↗

Role of genetic polymorphisms on opioid safety and efficacy in cancer pain: A systematic review and meta-analysis.Semantic proximity Read ↗

Pharmacogenomics and Morphine.Semantic proximity Read ↗

[Interindividual variation of pharmacokinetic disposition of and clinical responses to opioid analgesics in cancer pain patients].Semantic proximity Read ↗

Association Between Human Pain-Related Genotypes and Variability in Opioid Analgesia: An Updated Review.Semantic proximity Read ↗

Sequence variations in the UDP-glucuronosyltransferase 2B7 (UGT2B7) gene: identification of 10 novel single nucleotide polymorphisms (SNPs) and analysis of their relevance to morphine glucuronidation in cancer patients.Semantic proximity Read ↗

Role of pharmacogenetics in variable response to drugs: focus on opioidsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.